T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$2.81B |
| 2 |
Boeing
BA
|
+$1.68B |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$1.33B |
| 4 |
Amphenol
APH
|
+$1.11B |
| 5 |
CME Group
CME
|
+$902M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$3.65B |
| 2 |
Advanced Micro Devices
AMD
|
+$2.51B |
| 3 |
UnitedHealth
UNH
|
+$2.06B |
| 4 |
Uber
UBER
|
+$1.84B |
| 5 |
Adobe
ADBE
|
+$1.44B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.21% |
| 2 | Healthcare | 12.77% |
| 3 | Consumer Discretionary | 11.71% |
| 4 | Financials | 11.15% |
| 5 | Communication Services | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2901
Wheels Up
UP
$137M
| $59K | ﹤0.01% |
1,764
+321
| +22% | +$13.5K |
|
2902
ADC Therapeutics
ADCT
$162M
| $58K | ﹤0.01% |
28,831
| – | – |
|
|
WW
2903
DELISTED
WW International
WW
| $58K | ﹤0.01% |
45,100
| – | – |
|
2904
Caribou Biosciences
CRBU
$133M
| $57K | ﹤0.01% |
35,848
+8,008
| +29% | +$16.1K |
|
2905
Lexicon Pharmaceuticals
LXRX
$796M
| $57K | ﹤0.01% |
77,502
-39,677
| -34% | -$47.8K |
|
|
AIRJW
2906
AirJoule Technologies Warrant
AIRJW
$56.3M
| $57K | ﹤0.01% |
56,154
| – | – |
|
|
QVCGA
2907
DELISTED
QVC Group Inc Series A
QVCGA
| $57K | ﹤0.01% |
3,417
| – | – |
|
2908
Coherus Oncology
CHRS
$175M
| $56K | ﹤0.01% |
40,169
| – | – |
|
2909
Editas Medicine
EDIT
$396M
| $56K | ﹤0.01% |
43,777
-21,041
| -32% | -$53.6K |
|
|
IAUX
2910
i-80 Gold Corp
IAUX
$1.51B
| $56K | ﹤0.01% |
116,457
+12,687
| +12% | +$10.3K |
|
2911
Sutro Biopharma
STRO
$265M
| $56K | ﹤0.01% |
3,020
+394
| +15% | +$12K |
|
2912
Clarus
CLAR
$137M
| $55K | ﹤0.01% |
12,069
-3,682
| -23% | -$16.5K |
|
2913
Intellicheck
IDN
$48.4M
| $55K | ﹤0.01% |
19,500
| – | – |
|
|
INZY
2914
DELISTED
Inozyme Pharma
INZY
| $55K | ﹤0.01% |
19,533
+2,930
| +18% | +$11.1K |
|
2915
Lineage Cell Therapeutics
LCTX
$260M
| $55K | ﹤0.01% |
108,204
| – | – |
|
|
FARM
2916
DELISTED
Farmer Brothers
FARM
| $54K | ﹤0.01% |
29,600
| – | – |
|
2917
Future Fuel
FF
$225M
| $54K | ﹤0.01% |
+10,155
| New | +$56.7K |
|
|
MAPS
2918
DELISTED
WM TECHNOLOGY INC A
MAPS
| $54K | ﹤0.01% |
38,765
+11,573
| +43% | +$12.4K |
|
|
SCPH
2919
DELISTED
scPharmaceuticals
SCPH
| $54K | ﹤0.01% |
+15,143
| New | +$58K |
|
|
TSVT
2920
DELISTED
2seventy bio
TSVT
| $54K | ﹤0.01% |
18,225
-10,987
| -38% | -$45.1K |
|
2921
Full House Resorts
FLL
$62.3M
| $53K | ﹤0.01% |
12,748
+2,340
| +22% | +$11.1K |
|
2922
LiveOne
LVO
$32.1M
| $53K | ﹤0.01% |
3,595
+1,390
| +63% | +$12.1K |
|
2923
Zura Bio
ZURA
$387M
| $53K | ﹤0.01% |
20,830
+5,506
| +36% | +$19.6K |
|
2924
Purple Innovation
PRPL
$10.8M
| $52K | ﹤0.01% |
2,666
| – | – |
|
2925
Rekor Systems
REKR
$55.6M
| $52K | ﹤0.01% |
33,163
+10,159
| +44% | +$10.5K |
|
Similar funds
T. Rowe Price Associates's Q4 2024 Portfolio in Review
As of Q4 2024, T. Rowe Price Associates held 3,110 positions worth $867B, down 0.13% from $869B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
T. Rowe Price Associates's Q4 2024 filing shows 92 new, 1,805 increased, 946 reduced and 96 closed positions. Its largest new stake was South Bow Corp: 12,337,055 shares worth $291M. The largest sale was Apple, an estimated $3.65B.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 32% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2024 buy was South Bow Corp: 12,337,055 shares worth $291M.
- T. Rowe Price Associates added most to Broadcom in Q4 2024, an estimated $2.81B increase.
- T. Rowe Price Associates's biggest Q4 2024 reduction was Apple, cutting an estimated $3.65B.
- T. Rowe Price Associates fully exited Tempus AI in Q4 2024, selling an estimated $292M.
- T. Rowe Price Associates's ten largest holdings make up 35% of its $867B portfolio in Q4 2024.
- T. Rowe Price Associates opened 92 new positions and closed 96 in Q4 2024.
- T. Rowe Price Associates's portfolio value fell 0.13% quarter-over-quarter to $867B.
Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.